Clinical trial
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients…
NCT00413413 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00413413 |
|---|---|
| Title | Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension |
| Official title | A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Valsartan/amlodipine 80/5 mg, Valsartan 80 mg, Valsartan 160 mg |
| Enrollment | 1,134 |
| Start date | Jan 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Dec 19, 2006 |
| Last update posted | Apr 28, 2011 |
| Countries | China |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: